Katy Beckermann, MD, PhD
Kathryn Beckermann, MD, PhD, is an Assistant Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, at Vanderbilt University Medical Center. She is a GU medical oncologist specialized in treating kidney, bladder, prostate, and testicular cancer.
Articles by Katy Beckermann, MD, PhD
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Drs. Beckermann and Barata explore the implications of the negative findings of the CONTACT-03 trial on clinical practice.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
The challenges of patient management and access to care are explored in the sixth part of our RLT roundtable discussion.
The fifth segment of the RLT roundtable explores recent clinical trials, including the VISION study.
The fourth part of this roundtable delves into the VISION and PSMAfore studies and their implications.
The third part of this roundtable explores imaging interpretation and toxicity management.
An expert panel discusses the evolving landscape of radioligand therapy for prostate cancer.
The panel discusses the role of PSMA imaging in prostate cancer, theranostics, and radioligand therapy.
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 
Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.